On February 27, 2020, KTL (Stock Code: EB7), a Singapore listed company, issued its 2019 annual financial report. According to the financial report, KTL has finally changed the embarrassing situation of three consecutive years and annual loss of about SGD 20 million, achieving a remarkable achievement of financial profit and net profit of SGD 10.814 million (Approximate RMB 55 million).

 

 

KTL group is a main board listed company with a history of 100 years in Singapore (Stock Code: EB7). KTL has established subsidiaries in many countries and regions around the world, covering navigation and other different sectors and fields, with strong comprehensive strength and good international business reputation. In 2019, KTL seeks diversified business development and achieves BOP strategic cooperation with Lvbao Medical Technology Co., Ltd, which also marks an important step for KTL to enhance its business rapidly and comprehensively.

 

In 2019, the performance turned from loss to profit, which is inseparable from Lvbao Medical, the main business segment of KTL. Lvbao Medical Technology Co., Ltd is a national high-tech platform enterprise, integrating Internet of things, e-commerce, pharmaceutical products, information technology, intelligent manufacturing, software development, production and operation. After years of development, Lvbao Group has established a provincial operation company with the brand of "Huwa" in more than 20 provinces. The “Huwa” intelligent convenient pharmacy system" has been put into operation in more than 2000 3A and 2A hospitals nationwide, with the largest market scale in China. So far, it has provided convenient and affordable medical extension product purchase services for tens of millions of patients.

 

In addition, Lvbao Group's main business also includes four sectors: Huwa intelligent convenience pharmacy system, Huwa grass-roots medical convenience diagnosis and treatment system, Huwa medicine new media platform and Huwa health online mall.

 

In 2019, KTL, together with Lvbao, has established "Huwa development fund" with Pacific Fund, a famous international capital brand, and Raffles Fund. It is planned to select partners in 1 million primary medical institutions nationwide in three years to provide "primary medical convenience diagnosis and treatment system" free of charge for upgrading, We will build a service system of "grassroots medical convenience diagnosis and treatment platform" with the strongest strength and the largest scale in China, so as to realize the enterprise mission of "making medical treatment and drug purchase more convenient and affordable".

 

At present, the Covid-19 virus is epidemic and getting worse in the world, the development demand of intelligent medical industry is more and more intense. Huwa intelligent convenient pharmacy system changes the way of waiting in line when taking medicine, avoids face-to-face contact between people, and greatly reduces the probability of cross infection. KTL has accurately captured the development opportunities of the industry. It is expected that in five years, KTL will work with Lvbao to put more than 50000 Huwa intelligent convenience pharmacy platform equipment in the country, and 50000 medical institutions will be stationed in the basic medical convenience diagnosis and treatment platform. We are looking forward to a higher level of KTL 2020.

 

Disclaimer: there are risks in the market, make your choice with care. This article is for reference only, not for sale.